...
首页> 外文期刊>Journal of Translational Medicine >Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms
【24h】

Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms

机译:Ph阴性骨髓增生性肿瘤中miR-34a,miR-34b / c,miR-124-1和miR-203的甲基化

获取原文
           

摘要

Background MicroRNA (miR) miR-34a, -34b/c, -124-1 and -203 are tumor suppressor miRs implicated in carcinogenesis. Methods We studied DNA methylation of these miRs in Philadelphia-negative (Ph-ve) myeloproliferative neoplasms (MPNs). Methylation-specific PCR (MSP), verified by direct sequencing of the methylated MSP products, was performed in cell lines, normal controls and diagnostic marrow samples of patients with MPNs. Results Methylation of these miRs was absent in the normal controls. miR-34b/c were homozygously methylated in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with miR silencing, and 5-aza-2'-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was methylated in one patient and none had methylation of miR-124-1. Seven patients (15.6%) had methylation of at least one of the four miRs. miR methylation did not correlate with clinical parameters, disease complications or JAK2 V617F mutation. Conclusion This is the first report of miR hypermethylation in MPNs. miR-203 hypermethylation is not specific to Ph+ve leukemias but also present in Ph-ve MPNs. miR-34b/c methylation was associated with reversible miR silencing. There was no correlation of miR methylation with clinical demographic data or outcome.
机译:背景MicroRNA(miR)miR-34a,-34b / c,-124-1和-203是与癌变有关的肿瘤抑制miR。方法我们研究了费城阴性(Ph-ve)骨髓增生性肿瘤(MPNs)中这些miR的DNA甲基化。甲基化特异性PCR(MSP)已通过对MPN患者的细胞系,正常对照和诊断性骨髓样本进行了甲基化MSP产品直接测序验证。结果正常对照中没有这些miR的甲基化。 miR-34b / c在HEL细胞中被纯合甲基化,而在MEG-01中被杂合化。在HEL细胞中,纯合的miR-34b / c甲基化与miR沉默相关,而5-氮杂2'-脱氧胞苷处理导致miR-34b和miR-34c的重新表达,这与两个miR都在调控同一启动子CpG岛。 miR-34a在MEG-01和K-562中杂合了甲基化。 miR-203在K-562和SET-2中完全未甲基化,但在HEL和MEG-01中均未发现MSP扩增,提示miR缺失。在主要样本中,每个样本有四个miR-34b / c和-203甲基化,其中两个样本同时具有miR-34b / c和-203甲基化。一名患者出现了miR-34a甲基化,而miR-124-1没有一个甲基化。七名患者(15.6%)的甲基化程度至少为四个miR之一。 miR甲基化与临床参数,疾病并发症或JAK2 V617F突变无关。结论这是MPN中miR高甲基化的首次报道。 miR-203高度甲基化并非特定于Ph + ve白血病,但也存在于Ph-ve MPN中。 miR-34b / c甲基化与可逆的miR沉默有关。 miR甲基化与临床人口统计学数据或结果无相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号